Ocular Therapeutix, Inc. (OCUL) is a publicly traded Healthcare sector company. As of November 2, 2026, OCUL trades at $6.86 with a market cap of $1.53B and a P/E ratio of -5.15. OCUL moved -0.86% today. Year to date, OCUL is -41.03%; over the trailing twelve months it is -41.03%. Its 52-week range spans $5.80 to $16.44. Analyst consensus is strong buy with an average price target of $24.13. Rallies surfaces OCUL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for OCUL, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $6.86 |
| Market Cap | $1.53B |
| P/E Ratio | -5.15 |
| EPS | $-1.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.44 |
| 52-Week Low | $5.80 |
| Volume | 67.50K |
| Avg Volume | 0 |
| Revenue (TTM) | $52.05M |
| Net Income | $-301.45M |
| Gross Margin | 87.11% |
9 analysts cover OCUL: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.13.